Status:
RECRUITING
Prediction of Portal Hypertension in Patients With CVID (CVID-pHT)
Lead Sponsor:
University Hospital Freiburg
Conditions:
Non-Cirrhotic Portal Hypertension
Common Variable Immunodeficiency
Eligibility:
All Genders
18+ years
Brief Summary
Patients with CVID will be offered to participate in this observational trial during the routine annual visit in the outpatient clinic at the Center of chronic Immunodeficiency (CCI) of the University...
Detailed Description
Patients with CVID can be included in the study. The study cohort will consist of three subgroups: 1) Patients with CVID and autoimmunity, but no liver involvement. 2) Patients with CVID and liver inv...
Eligibility Criteria
Inclusion
- Patients with CVID
Exclusion
- no written informed consent
- concomitant chronic liver disease (viral hepatitis, alcoholic liver disease, steatitic liver disease, hemochromatosis, primary biliary cholangitis, primary sclerosis cholangitis, M. Wilson, alpha-1-antitrypsin deficiency)
Key Trial Info
Start Date :
November 1 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2025
Estimated Enrollment :
250 Patients enrolled
Trial Details
Trial ID
NCT06145100
Start Date
November 1 2023
End Date
December 31 2025
Last Update
December 9 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Medical Center Freiburg, Department of Medicine II
Freiburg im Breisgau, Germany, 79106